Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KO-947 in Advanced Non-Hematological Malignancies
NCT03051035Phase 1Terminated
- Sponsor
- Kura Oncology
- Start
- Apr 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of KO-947 in solid tumor, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC) and 1 more, sponsored by Kura Oncology. Primary endpoint: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 28 days. Started Apr 2017; status: terminated.
02
Drugs
KO-947
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03051035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051035.